Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Explores the Cardiovascular Drugs Potential in KSA and UAE - A complimentary analyst briefing to be hosted on April 20 at 4:30 pm UAE time
Frost & Sullivan Explores the Cardiovascular Drugs Potential in KSA and UAE

 

PRZOOM - /newswire/ - Dubai, UAE, United Arab Emirates, 2011/04/19 - A complimentary analyst briefing to be hosted on April 20 at 4:30 pm UAE time.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Healthcare Practice at Frost & Sullivan, a Global Growth Partnership Company, is pleased to host an Analyst Briefing titled ‘Cardiovascular Drugs holds the potential in KSA and UAE: Know the market trends – current and future’, scheduled for Wednesday, April 20th, 2011 at 4:30 pm U.A.E Time.

The growing burden of Cardiovascular and allied diseases has ushered opportunity for pharmaceutical companies globally with their cardiovascular drug portfolio. To successfully foray and operate in any geographic market require an in-depth understanding of market dynamics, trends and future scenario of the market. This briefing aims to provide an in-depth coverage of the cardiovascular drugs market in private channel including segments such as anti-hypertensive and lipid lowering.

This briefing is going to benefit the companies who are either considering an entry into these markets or a new entrant with their cardiovascular product portfolio. Apart from pharmaceutical companies, channel partners and investors will derive benefit from such briefing.

Highlights of the briefing include analysis of external challenges such as drivers and restraints, revenue trends and forecast overall cardiovascular drugs market and its market segments.

According to Frost & Sullivan,“The KSA and UAE markets for cardiovascular drugs hold great potential for pharmaceutical companies with skewed demographic profile towards baby boomers, higher incidences of lifestyle diseases including cardiovascular ailments, diabetes, etc. and a prosperous economy. Frost & Sullivan’s latest analyst briefing will examine the value proposition offered by the KSA and UAE cardiovascular markets and evaluate their position as potential markets for pharmaceutical players.”

To participate in this briefing, or for an interview, please contact Tanu Chopra/ Nimisha Iyer at tanu.chopra[.]frost.com / niyer[.]frost.com with the following information: your full name, company name, title, telephone number, office email id, address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing by submitting the aforementioned details.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from 40 offices across six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Explores the Cardiovascular Drugs Potential in KSA and UAE

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Tanu Chopra / Nimisha Iyer 
+91.22. 6607 2037 / +91 98200 50519 tanu.chopra[.]frost.com / niyer[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today